pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,354 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1645Endpoints1294BioSpace614Fierce Biotech613BioPharma Dive486raps206onclive165fda recalls107fda medwatch
therapy area
allOncology11558Rare Disease2903Immunology2678Cardiology2349Pulmonology2021Hematology1958Vaccines1711Psychiatry & CNS1124
  • Nurse practitioner students struggle to find clinical preceptors, often paying thousands
    Nurse practitioner graduate programs require students to complete at least 500 hours of supervised patient care with a licensed preceptor. Across the United States, a shortage of qualified precepto…
    STAT · 2mo agoNegative↗ source
  • Retired cardiologist finds new purpose volunteering at Maryland community clinic, highlights gaps in US health care
    A cardiologist who spent nearly four decades in private practice retired in 2022 and soon after began volunteering at a nonprofit community clinic in Maryland. The clinic serves the "working poor"…
    STAT · 2mo agoNeutral↗ source
← prev
page 96 of 215
next →
96
globenewswire health73
fda press55
Ophthalmology896
Endocrinology & Metabolism716
Pain687
Nephrology682
Texas lawmaker warns Chinese biotech firms gaining early-stage advantage over U.S. industry
Rep. Nathaniel Moran, a Republican from Texas and member of the House Select Committee on China, told Fierce that the United States is overlooking how Chinese biotech companies are outpacing Americ…
Fierce Biotech · 2mo agoNeutral↗ source
  • Merck and Moderna report positive topline results for personalized cancer vaccine
    A third death was reported in China’s expedited clinical trials, raising safety concerns for fast‑track studies in the region. Merck and Moderna announced positive topline data from their personal…
    Endpoints · 2mo agoPositive readoutPositive↗ source
  • Everything Sprouts recalls alfalfa sprouts over possible E. coli and Salmonella contamination
    Everything Sprouts, LLC, a Minneapolis‑based producer, announced a recall of certain lots of its alfalfa sprouts on August 22, 2026. The recall was triggered because the sprouts may be contaminate…
    fda recalls · 2mo agoCRLNegative↗ source
  • Lilly leads GLP-1 weight-loss market while Novo Nordisk’s Wegovy exceeds expectations but falls short of forecasts
    Eli Lilly and Novo Nordisk are intensifying their battle for dominance in the multibillion‑dollar GLP‑1 weight‑loss market, with each company promoting its own set of injectable therapies and pipel…
    BioPharma Dive · 2mo agoEarningsNeutral↗ source
  • Cure for HIV must protect long-term survivors from loss of benefits
    The authors, a postdoctoral researcher, a long‑term HIV survivor, and the head of a survivor alliance, argue that a future HIV cure should not jeopardize the support systems that have kept many pat…
    STAT · 2mo agoNeutral↗ source
  • US lawmakers push FDA to tighten rules on Chinese clinical data after three gene therapy deaths
    Three recent deaths in separate gene‑therapy trials in China have prompted two members of the U.S. House of Representatives to call on the FDA for new safeguards. Representatives John Moolenaar an…
    BioSpace · 2mo agoRegulatoryNegative↗ source
  • Roche's Genentech to invest $750 million to double Oregon manufacturing site
    Roche's Genentech announced a $750 million investment to expand its existing production facility in Oregon, with the goal of doubling its capacity. The expanded site is expected to boost manufactu…
    STAT · 2mo agoDealNeutral↗ source
  • Takeda wins FDA nod for orexin drug oveporexton, first treatment for narcolepsy type 1 and potential broader uses
    Takeda received FDA approval for oveporexton (brand Orzeyful), an orexin receptor agonist, marking the first approved therapy that targets the orexin system for narcolepsy type 1. The drug mimics…
    Fierce Biotech · 2mo agoApprovalPositive↗ source
  • HHS seeks public input on new vaccine recommendation categories under Trump and Kennedy
    A request for information was posted by the Department of Health and Human Services, giving the public a 30‑day window to comment on potential changes to the U.S. vaccine recommendation framework.…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Genentech pours $750M into new drug‑delivery device plant in Oregon; Bavarian Nordic pushes back Lyme vaccine trial
    Roche’s Genentech announced a $750 million investment to build a new drug‑delivery device manufacturing facility at its Hillsboro, Oregon campus. The plant is intended to expand the company’s capac…
    Endpoints · 2mo agoDealNeutral↗ source
  • Werewolf Therapeutics merges with Ambros in $150M deal to advance non‑opioid painkiller for rare limb injury syndrome
    Werewolf Therapeutics and Ambros Therapeutics announced a merger valued at $150 million, creating a new company that will retain the Ambros name. The deal includes a private placement to fund the…
    BioSpace · 2mo agoDealPositive↗ source
  • Study suggests cancer patients may be receiving higher doses and longer treatment courses than needed
    Recent analysis highlighted that many cancer patients are being treated with larger drug doses and extended therapy durations than may be medically necessary. The pattern raises concerns about unn…
    STAT · 2mo agoNegative↗ source
  • Merck’s Ebola vaccine rolled out in the Democratic Republic of Congo
    Scientists have begun administering Merck’s Ebola vaccine in the Democratic Republic of Congo as part of ongoing outbreak response efforts. The vaccine, previously used in emergency settings, is b…
    STAT · 2mo agoPositive↗ source
  • New study warns that Trump-era cuts to federal research could jeopardize cancer drug development
    A recent study examines how recent political moves to curtail federally funded research could affect cancer drug development. The analysis notes that over the past decade biopharma companies have…
    Endpoints · 2mo agoRegulatoryNegative↗ source
  • Novo Nordisk launches Phase 3 trial of lower maintenance doses of oral Wegovy for obesity
    Novo Nordisk has begun a Phase 3, placebo-controlled study called OASIS 5 to evaluate two lower oral doses of its GLP-1 weight-loss drug Wegovy (semaglutide) in people who are obese or overweight.…
    BioSpace · 2mo agoCRLNeutral↗ source
  • Replimune appoints former Genentech exec Michelle DiNapoli as chief commercial officer after accelerated melanoma approval
    Replimune announced that Michelle DiNapoli will become its chief commercial officer, starting August 18. DiNapoli previously held senior roles at Genentech, where she led commercial operations. Th…
    Endpoints · 2mo agoPositive↗ source
  • Ambros Therapeutics merges with Werewolf, raises $150M to fund phase 3 trial of rare disease drug
    Ambros Therapeutics announced an all‑stock reverse merger with Werewolf Therapeutics, accompanied by a $150 million private placement. The transaction will see the combined company operate under th…
    Fierce Biotech · 2mo agoDealPositive↗ source
  • New study shows focal therapy matches surgery and radiation survival while reducing side effects in localized prostate cancer
    Physicians remain split over focal therapy for localized prostate cancer, a technique that targets MRI‑visible lesions with heat, cold, or other energy sources instead of removing the entire gland.…
    STAT · 2mo agoPositive readoutNeutral↗ source
  • FDA issues early alert on Medical Action epidural kits containing recalled sodium chloride ampules
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert warning about certain epidural kits from Medical Action Industries. The alert notes that the kits include sodium chlor…
    fda medwatch · 2mo agoRegulatoryNegative↗ source
  • Capricor shareholders face board overhaul push as investors demand meeting and capital-preservation plan amid DMD cell therapy delay
    Kaos Capital, describing itself as a significant shareholder of Capricor Therapeutics, sent a letter to fellow investors calling for an immediate meeting, a change of the board, and a capital-prese…
    BioSpace · 2mo agoNegative↗ source
  • HHS Secretary RFK Jr. seeks to soften U.S. vaccine recommendations
    HHS Secretary Robert F. Kennedy Jr. has issued a request for information seeking to soften government vaccine recommendations. The request, released on Friday, signals that the administration is s…
    Endpoints · 2mo agoRegulatoryNegative↗ source
  • Activist Kaos Capital pushes governance overhaul at Capricor ahead of FDA Duchenne decision
    Activist investor Kaos Capital has sent a letter to Capricor Therapeutics shareholders demanding a “governance reset.” The firm asks for a meeting to nominate two independent directors, create an M…
    BioPharma Dive · 2mo agoNegative↗ source
  • GOP lawmakers urge FDA to reject Chinese trial data unless sites undergo recent agency audit
    Two Republican members of the U.S. House have asked the Food and Drug Administration to tighten its oversight of clinical data that originates from China. Their proposal would require the FDA to r…
    Endpoints · 2mo agoRegulatoryNegative↗ source